Phase 1/2 Trial of AMT-130 Gene Therapy Enrolling High-dose Group

Phase 1/2 Trial of AMT-130 Gene Therapy Enrolling High-dose Group

297375

Phase 1/2 Trial of AMT-130 Gene Therapy Enrolling High-dose Group

The first two patients have been enrolled in the high-dose group of a U.S. clinical trial testing the safety and efficacy of AMT-130 as a potential gene therapy for Huntington’s disease. “We are very pleased with the progress that we continue to make in this Phase 1/2 clinical trial and that we are now administering AMT-130 at the higher dose,” Ricardo Dolmetsch, PhD, president of research and development at uniQure, the therapy’s developer, said in a press…

You must be logged in to read/download the full post.